Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

ClinicalTrials.gov ID: NCT07648264

Public ClinicalTrials.gov record NCT07648264. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Prospective, Open-label, Multicenter, Single-arm Study to Investigate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Subjects With Secondary Immune Deficiency Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

Study identification

NCT ID: NCT07648264
Recruitment status: Not yet recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: CSL Behring; Industry
Enrollment: 63 participants

Conditions and interventions

Conditions

Secondary Immune Deficiency

Interventions

IgPro20 Biological

Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 23, 2026
Primary completion: Feb 15, 2029
Completion: Feb 15, 2029
Last update posted: Jul 21, 2026

2026 – 2029

United States locations

U.S. sites: 17
U.S. states: 13
U.S. cities: 17

Facility	City	State	ZIP	Site status
UC Irvine	Orange	California	92868	—
CBCI, Colorado Blood Cancer Institute	Denver	Colorado	80218	—
SSAK Partners	Coral Springs	Florida	33065	—
Mayo Clinic - Jacksonville	Jacksonville	Florida	32224	—
Indiana University Health Arnett, Inc.	Lafayette	Indiana	47904	—
Johns Hopkins Asthma & Allergy Center	Baltimore	Maryland	21224	—
American Oncology Partners, PA dba The Center for Cancer and Blood Disorders	Bethesda	Maryland	20817	—
Hackensack Meridian Health	Hackensack	New Jersey	07601	—
Carol G Simon Cancer Center	Morristown	New Jersey	07960	—
David H. Koch Center for Cancer Care	New York	New York	10065	—
Montefiore Medical Center PRIME	The Bronx	New York	10467	—
Duke University	Durham	North Carolina	27710	—
University of Cincinnati Medical Center	Cincinnati	Ohio	45219	—
Penn State Hershey Medical Center	Hershey	Pennsylvania	17033	—
The University of Texas MD Anderson Cancer Center	Houston	Texas	77030	—
Fred Hutchinson Cancer Research Center	Seattle	Washington	98109	—
Medical College of Wisconsin	Milwaukee	Wisconsin	53226	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 43 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07648264, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 21, 2026 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07648264 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →